Skip to main content Help with accessibility Skip to main navigation

RANIBIZUMAB intravitreal injection (Lucentis®) for choroidal neovascularisation (non-NICE indications)

CCG Approval Status:

Date Added: 25 - Sep - 2019
Body System:

The Pan Mersey Area Prescribing Committee recommends the prescribing of RANIBIZUMAB intravitreal injection (Lucentis®), by ophthalmologists only, for the treatment of visual impairment secondary to choroidal neovascularisation (CNV) in conditions not covered by NICE technology appraisals.